Nicole Graf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Graf has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Charlton
The Children’s Hospital at Westmead
2 shared publications - Deirdre Hahn
Department of Nephrology, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, Australia, 2145
2 shared publications A Coulomb
APHP‐Sorbonne University Paris France
1 shared publicationA. Lorentz
1 shared publication- Adam Bournazos
The University of Sydney, Faculty of Medicine and Health, School of Medical Sciences, Sydney, Australia
1 shared publication - Alan Ma
Department of Clinical Genetics Sydney Children's Hospitals Network Westmead Australia
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Springer Nature in Molecular Systems Biology
- Vol. 21 (12) , 1748-1777
High-throughput 3D engineered paediatric tumour models for precision medicine
Precision medicine for paediatric and adult cancers that incorporates drug sensitivity profiling can identify effective therapies for individual patients. However, obtaining adequate biopsy samples for high-throughput (HTP) screening remains challenging, with tumours needing to be expanded in culture or patient-derived xenografts, this is time-consuming and often unsuccessful. Herein, we have developed paediatric patient-derived tumour models using an engineered extracellular matrix (ECM) tissue mimic hydrogel system and HTP 3D bioprinting. Gene expression analysis from a neuroblastoma and sarcoma paediatric patient cohort identified key components of the ECM in these tumour types. Engineered hydrogels with ECM-mimic peptides were used to bioprint and create patient-specific tumouroids using patient-derived cells from xenograft models, and the approach was further confirmed on direct patient tumour samples. Bioprinted tumouroids from the PDX models recapitulated the genetic and phenotypic characteristics of the original tumours and retained tumourigenicity. HTP drug screening of these models identified individualised drug sensitivities. Our approach offers a timely and clinically relevant technology platform for precision medicine in paediatric cancers, potentially transforming preclinical testing across multiple cancer types.
- 1 October 2025
- Published by Springer Nature in Molecular Systems Biology
- Vol. 21 (12) , 1748-1777
Open AccessHigh-throughput 3D engineered paediatric tumour models for precision medicine
Precision medicine for paediatric and adult cancers that incorporates drug sensitivity profiling can identify effective therapies for individual patients. However, obtaining adequate biopsy samples for high-throughput (HTP) screening remains challenging, with tumours needing to be expanded in culture or patient-derived xenografts, this is time-consuming and often unsuccessful. Herein, we have developed paediatric patient-derived tumour models using an engineered extracellular matrix (ECM) tissue mimic hydrogel system and HTP 3D bioprinting. Gene expression analysis from a neuroblastoma and sarcoma paediatric patient cohort identified key components of the ECM in these tumour types. Engineered hydrogels with ECM-mimic peptides were used to bioprint and create patient-specific tumouroids using patient-derived cells from xenograft models, and the approach was further confirmed on direct patient tumour samples. Bioprinted tumouroids from the PDX models recapitulated the genetic and phenotypic characteristics of the original tumours and retained tumourigenicity. HTP drug screening of these models identified individualised drug sensitivities. Our approach offers a timely and clinically relevant technology platform for precision medicine in paediatric cancers, potentially transforming preclinical testing across multiple cancer types.
- Open Access
- 15 April 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 183-196
Data set for reporting paediatric renal tumours: recommendations from the international collaboration on cancer reporting (ICCR)
Tumours arising within the developing kidney of children vary widely in their histological appearance and outcome; optimal therapy requires accurate classification and staging. The two major paediatric cooperative groups provide different therapeutic protocols based on different staging and classification, initially developed to serve patients in North America and Europe, but also used in many other parts/regions of the world. The International Collaboration on Cancer Reporting (ICCR) has developed a structure whereby such complex information may be harmonised, and able to be applied to patients globally. An international expert panel consisting of paediatric pathologists and oncologists produced a set of items critical to cancer reporting and subjected these to review and discussion using the structured processes provided by the ICCR. A formal ICCR structure was assembled, and consensus surrounding elements and their application to different therapeutic protocols was developed. The data set underwent open international consultation. This resulted in the first international data set for Wilms tumour (WT) and other paediatric renal tumours, provided herein. The use of ICCR methods enables a full understanding of highly complex and often overlapping reporting elements by international experts, and the potential of developing a set of commonly applied data elements that are fully defined. This sets the groundwork for future consolidation of definitions and harmonisation of therapies for WT and other paediatric renal tumour patients. It also allows institutions outside the major paediatric cooperative groups to provide therapy based on known elements.
- 15 April 2025
- Published by Wiley in Histopathology
- Vol. 87 (2) , 183-196
Open AccessData set for reporting paediatric renal tumours: recommendations from the international collaboration on cancer reporting (ICCR)
Tumours arising within the developing kidney of children vary widely in their histological appearance and outcome; optimal therapy requires accurate classification and staging. The two major paediatric cooperative groups provide different therapeutic protocols based on different staging and classification, initially developed to serve patients in North America and Europe, but also used in many other parts/regions of the world. The International Collaboration on Cancer Reporting (ICCR) has developed a structure whereby such complex information may be harmonised, and able to be applied to patients globally. An international expert panel consisting of paediatric pathologists and oncologists produced a set of items critical to cancer reporting and subjected these to review and discussion using the structured processes provided by the ICCR. A formal ICCR structure was assembled, and consensus surrounding elements and their application to different therapeutic protocols was developed. The data set underwent open international consultation. This resulted in the first international data set for Wilms tumour (WT) and other paediatric renal tumours, provided herein. The use of ICCR methods enables a full understanding of highly complex and often overlapping reporting elements by international experts, and the potential of developing a set of commonly applied data elements that are fully defined. This sets the groundwork for future consolidation of definitions and harmonisation of therapies for WT and other paediatric renal tumour patients. It also allows institutions outside the major paediatric cooperative groups to provide therapy based on known elements.
- Open Access
- 13 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6818
Infantile Sinonasal Tract Myxomas with Orbital Involvement: Presentation of Two Cases and Comprehensive Literature Review
Objective: Our aim is to present two cases of infantile sinonasal tract myxoma with orbital involvement and conduct a comprehensive literature review of the topic. We aim to provide a summary of the presentation of infantile sinonasal tract myxomas to effectively aid clinicians in considering this rare entity as a potential diagnosis. Methods: We present a case series and a retrospective review of the published literature in the English language. A search was conducted between 1945 and 2023 on sinonasal myxoma. Cases of infantile (<3 years) sinonasal myxoma in the literature were reported as well as two cases of our own. Data was collected from each of the identified articles on the age of presentation, sex, initial presentation, tumor location, imaging, pathology, and treatment. Results: Forty-eight cases of sinonasal myxoma in children <3 years of age were identified. These cases had a slight male preponderance (F:M, 1:1.39) and an average age of diagnosis of sixteen months. Of the cases included, the majority involved the maxilla and maxillary sinuses (83.3%) and commonly presented with a painless slow-growing mass in the region of the tumor. Characteristic CT findings are homogenous solid masses with heterogeneous contrast enhancement. On MRI, these lesions appear hypointense on T1 with highly variable contrast enhancement and hyperintense on T2. Conclusions: We present two cases of infantile sinonasal myxoma with secondary orbital involvement followed by a major review. Treatment of these cases with surgical excision (confirmed clear margins) provided 0% rates of recurrence in the reported cases. Due to the rarity of these tumors and recent histological reclassification, a comprehensive review of this condition will assist clinicians in their management of it.
- 13 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6818
Open AccessInfantile Sinonasal Tract Myxomas with Orbital Involvement: Presentation of Two Cases and Comprehensive Literature Review
Objective: Our aim is to present two cases of infantile sinonasal tract myxoma with orbital involvement and conduct a comprehensive literature review of the topic. We aim to provide a summary of the presentation of infantile sinonasal tract myxomas to effectively aid clinicians in considering this rare entity as a potential diagnosis. Methods: We present a case series and a retrospective review of the published literature in the English language. A search was conducted between 1945 and 2023 on sinonasal myxoma. Cases of infantile (<3 years) sinonasal myxoma in the literature were reported as well as two cases of our own. Data was collected from each of the identified articles on the age of presentation, sex, initial presentation, tumor location, imaging, pathology, and treatment. Results: Forty-eight cases of sinonasal myxoma in children <3 years of age were identified. These cases had a slight male preponderance (F:M, 1:1.39) and an average age of diagnosis of sixteen months. Of the cases included, the majority involved the maxilla and maxillary sinuses (83.3%) and commonly presented with a painless slow-growing mass in the region of the tumor. Characteristic CT findings are homogenous solid masses with heterogeneous contrast enhancement. On MRI, these lesions appear hypointense on T1 with highly variable contrast enhancement and hyperintense on T2. Conclusions: We present two cases of infantile sinonasal myxoma with secondary orbital involvement followed by a major review. Treatment of these cases with surgical excision (confirmed clear margins) provided 0% rates of recurrence in the reported cases. Due to the rarity of these tumors and recent histological reclassification, a comprehensive review of this condition will assist clinicians in their management of it.
- Open Access
- 12 April 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (7) , 2677-2684
Kidney biopsy adequacy and complications in children — does technique matter?
Kidney biopsy is part of the diagnostic workup of many children with renal disease. Traditionally, a perpendicular approach to the biopsy has been used, but more recently, some proceduralists have favoured a tangential approach. It is not clear if one technique is superior with regards to tissue adequacy or complication rates. In our centre, interventional radiologists (IR) use general anaesthetic and a tangential approach, whereas paediatric nephrologists (PN) use sedation and a perpendicular approach. We examined consecutive native kidney biopsies performed between January 2008 and December 2017 for adequacy (sufficient tissue for light and electron microscopy and immunofluorescence) and examined the electronic medical records for data regarding technique and complications. IR performed 72 (29%) of the 245 native kidney biopsies, obtaining more total glomeruli (median 39 vs 16, p < 0.001) and more glomeruli per tissue core (median 13 vs 8, p < 0.001) than PN. No differences in specimen adequacy were observed between the two groups (79% IR vs 81% PN, p = 0.75) and a diagnosis could be made in 99% and 94% respectively (p = 0.1). A statistically lower rate of peri-nephric haematoma (28% vs 42%, p = 0.04) was detected in the IR group, but there were no significant differences in other complications. One patient required a blood transfusion (PN) and another required surgical intervention for a perinephric haematoma (IR).Conclusion: IR obtained larger samples and number of glomeruli, but the overall adequacy for native kidney biopsies was good using both perpendicular and tangential techniques, with low rates of significant complications. What is Known:• Kidney biopsy is integral to the diagnostic work-up of many children with kidney disease.• Kidney biopsy is a safe procedure with well-established complications in a minority of children. What is New:• Interventional radiologists had higher biopsy yield than paediatric nephrologists, possibly due to the tangential approach.• Biopsy adequacy rates are high using both techniques and provided a diagnosis in over 95% of cases.
- 12 April 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (7) , 2677-2684
Open AccessKidney biopsy adequacy and complications in children — does technique matter?
Kidney biopsy is part of the diagnostic workup of many children with renal disease. Traditionally, a perpendicular approach to the biopsy has been used, but more recently, some proceduralists have favoured a tangential approach. It is not clear if one technique is superior with regards to tissue adequacy or complication rates. In our centre, interventional radiologists (IR) use general anaesthetic and a tangential approach, whereas paediatric nephrologists (PN) use sedation and a perpendicular approach. We examined consecutive native kidney biopsies performed between January 2008 and December 2017 for adequacy (sufficient tissue for light and electron microscopy and immunofluorescence) and examined the electronic medical records for data regarding technique and complications. IR performed 72 (29%) of the 245 native kidney biopsies, obtaining more total glomeruli (median 39 vs 16, p < 0.001) and more glomeruli per tissue core (median 13 vs 8, p < 0.001) than PN. No differences in specimen adequacy were observed between the two groups (79% IR vs 81% PN, p = 0.75) and a diagnosis could be made in 99% and 94% respectively (p = 0.1). A statistically lower rate of peri-nephric haematoma (28% vs 42%, p = 0.04) was detected in the IR group, but there were no significant differences in other complications. One patient required a blood transfusion (PN) and another required surgical intervention for a perinephric haematoma (IR).Conclusion: IR obtained larger samples and number of glomeruli, but the overall adequacy for native kidney biopsies was good using both perpendicular and tangential techniques, with low rates of significant complications. What is Known:• Kidney biopsy is integral to the diagnostic work-up of many children with kidney disease.• Kidney biopsy is a safe procedure with well-established complications in a minority of children. What is New:• Interventional radiologists had higher biopsy yield than paediatric nephrologists, possibly due to the tangential approach.• Biopsy adequacy rates are high using both techniques and provided a diagnosis in over 95% of cases.
- Open Access
- 1 February 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (1) , e554
WGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase
Objective To describe the diagnostic utility of whole-genome sequencing and RNA studies in boys with suspected dystrophinopathy, for whom multiplex ligation-dependent probe amplification and exomic parallel sequencing failed to yield a genetic diagnosis, and to use remnant normal DMD splicing in 3 families to define critical levels of wild-type dystrophin bridging clinical spectrums of Duchenne to myalgia. Methods Exome, genome, and/or muscle RNA sequencing was performed for 7 males with elevated creatine kinase. PCR of muscle-derived complementary DNA (cDNA) studied consequences for DMD premessenger RNA (pre-mRNA) splicing. Quantitative Western blot was used to determine levels of dystrophin, relative to control muscle. Results Splice-altering intronic single nucleotide variants or structural rearrangements in DMD were identified in all 7 families. Four individuals, with abnormal splicing causing a premature stop codon and nonsense-mediated decay, expressed remnant levels of normally spliced DMD mRNA. Quantitative Western blot enabled correlation of wild-type dystrophin and clinical severity, with 0%–5% dystrophin conferring a Duchenne phenotype, 10% ± 2% a Becker phenotype, and 15% ± 2% dystrophin associated with myalgia without manifesting weakness. Conclusions Whole-genome sequencing relied heavily on RNA studies to identify DMD splice-altering variants. Short-read RNA sequencing was regularly confounded by the effectiveness of nonsense-mediated mRNA decay and low read depth of the giant DMD mRNA. PCR of muscle cDNA provided a simple, yet informative approach. Highly relevant to genetic therapies for dystrophinopathies, our data align strongly with previous studies of mutant dystrophin in Becker muscular dystrophy, with the collective conclusion that a fractional increase in levels of normal dystrophin between 5% and 20% is clinically significant.
- 1 February 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (1) , e554
Open AccessWGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase
Objective To describe the diagnostic utility of whole-genome sequencing and RNA studies in boys with suspected dystrophinopathy, for whom multiplex ligation-dependent probe amplification and exomic parallel sequencing failed to yield a genetic diagnosis, and to use remnant normal DMD splicing in 3 families to define critical levels of wild-type dystrophin bridging clinical spectrums of Duchenne to myalgia. Methods Exome, genome, and/or muscle RNA sequencing was performed for 7 males with elevated creatine kinase. PCR of muscle-derived complementary DNA (cDNA) studied consequences for DMD premessenger RNA (pre-mRNA) splicing. Quantitative Western blot was used to determine levels of dystrophin, relative to control muscle. Results Splice-altering intronic single nucleotide variants or structural rearrangements in DMD were identified in all 7 families. Four individuals, with abnormal splicing causing a premature stop codon and nonsense-mediated decay, expressed remnant levels of normally spliced DMD mRNA. Quantitative Western blot enabled correlation of wild-type dystrophin and clinical severity, with 0%–5% dystrophin conferring a Duchenne phenotype, 10% ± 2% a Becker phenotype, and 15% ± 2% dystrophin associated with myalgia without manifesting weakness. Conclusions Whole-genome sequencing relied heavily on RNA studies to identify DMD splice-altering variants. Short-read RNA sequencing was regularly confounded by the effectiveness of nonsense-mediated mRNA decay and low read depth of the giant DMD mRNA. PCR of muscle cDNA provided a simple, yet informative approach. Highly relevant to genetic therapies for dystrophinopathies, our data align strongly with previous studies of mutant dystrophin in Becker muscular dystrophy, with the collective conclusion that a fractional increase in levels of normal dystrophin between 5% and 20% is clinically significant.
- Open Access
- 1 July 2018
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 12, 1301-1309
Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC). Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT. Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (pp=0.065). One case of allergic reaction after fluorescein angiography and one case of ophthalmic migraine after ziv-aflibercept injection were documented. One case of reversible vision loss occurred during 6 months after combination therapy. No other adverse events or side effects were reported. Conclusion: Combination therapy of ziv-aflibercept and aflibercept with PDT seems to be beneficial, even in cases of chronic or repeatedly recurrent acute CSC. This includes cases of CSC resistant to or recurrent after medical treatment, PDT alone or therapy with anti-vascular endothelial growth factor alone.
- 1 July 2018
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 12, 1301-1309
Open AccessPhotodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
Purpose: The objective of the study was to assess the effect of off-label photodynamic therapy (PDT) in combination with intravitreal off-label ziv-aflibercept or off-label aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy (CSC). Patients and methods: Changes in best corrected visual acuity (BCVA) and subfoveal subretinal fluid (sSRF) and maximum subretinal fluid (mSRF) were retrospectively analyzed in a single-center cohort study of 17 patients (18 eyes) with persistent subretinal fluid for more than 3 months of duration of CSC. Treatment efficacy was measured between injection and PDT at 30±15 days, 90±15 days and 180±30 days after PDT. Results: Significant reduction of sSRF and mSRF was shown after therapy with ziv-aflibercept and aflibercept combined with PDT (pp=0.065). One case of allergic reaction after fluorescein angiography and one case of ophthalmic migraine after ziv-aflibercept injection were documented. One case of reversible vision loss occurred during 6 months after combination therapy. No other adverse events or side effects were reported. Conclusion: Combination therapy of ziv-aflibercept and aflibercept with PDT seems to be beneficial, even in cases of chronic or repeatedly recurrent acute CSC. This includes cases of CSC resistant to or recurrent after medical treatment, PDT alone or therapy with anti-vascular endothelial growth factor alone.
- 1 July 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (7) , 353-358
The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence
- 1 July 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (7) , 353-358
The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence